MYCO-002

MYCO-002 is an MDMA-like entactogen that is under development for the treatment of psychiatric disorders.

[1][2][3] It is said to be being developed towards the aim of improving the safety profile of MDMA.

[1][2] It was patented in July 2021 and received breakthrough therapy designation from the Food and Drug Administration (FDA) in November 2021.

[1] As of November 2021, MYCO-002 is in the preclinical research for treatment of psychiatric disorders.

This psychoactive drug-related article is a stub.